Publication Name	World Journal of Gastroenterology
Manuscript ID	6820
Country	Japan

Received	2013-10-29 11:53
Peer-Review Started	2013-10-29 19:26
To Make the First Decision	2013-11-21 19:04
Return for Revision	2013-11-22 10:31
Revised	2013-12-19 19:29
Second Decision	2014-03-19 13:53
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2014-03-19 15:14
Articles in Press
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2014-04-22 08:55
Publish the Manuscript Online	2014-04-29 09:53

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Topic Highlights
Article Title	Targeting receptor tyrosine kinases in gastric cancer
Manuscript Source	Invited Manuscript
All Author List	Asahiro Morishita, Jian Gong and Tsutomu Masaki
Funding Agency and Grant Number	Funding Agency Grant Number Ministry of Education, Culture, Sports, Science and Technology of Japan 25460998 (to Masaki T)
Corresponding Author	Asahiro Morishita, MD, PhD, Department of Gastroenterology and Neurology, Kagawa University School of Medicine, 1750-1 Ikenobe, Miki-cho, Kida-gun, Kagawa 761-0793, Japan. asahiro@med.kagawa-u.ac.jp
Key Words	Receptor tyrosine kinases; Gastric cancer; Epidermal growth factor receptor; Trastuzumab; Cetuximab; Lapatinib; Panitumumab; Erlotinib; Bevacizumab
Core Tip	Since the finding of receptor tyrosine kinases (RTKs) about thirty years ago, its functions have been examined over the years as key regulators of proliferation, differentiation, and metastasis. Several RTKs are activated in advanced gastric cancer (AGC) and various RTK inhibitors have been developed as tailored therapy. The results of recent clinical trials evaluate the effectiveness of targeting RTKs. Unfortunately, recent progress in the development of RTK-targeted therapy for AGC patients has been modest. To provide maximal therapeutic benefits, well-designed clinical trials and combinations with appropriate drugs are required. In addition, new predictive biomarkers are immediately obliged to guide the selection of a drug-sensitive patients’ population.
Publish Date	2014-04-29 09:53
Citation	Morishita A, Gong J, Masaki T. Targeting receptor tyrosine kinases in gastric cancer. World J Gastroenterol 2014; 20(16): 4536-4545
URL	http://www.wjgnet.com/1007-9327/full/v20/i16/4536.htm
DOI	http://dx.doi.org/10.3748/wjg.v20.i16.4536

Full Article (PDF)	WJG-20-4536.pdf
Full Article (Word)	WJG-20-4536.doc
Manuscript File	6820-Review.docx
Answering Reviewers	6820-Answering reviewers.pdf
Copyright License Agreement	6820-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate	6820-Language certificate.pdf
Peer-review Report	6820-Peer review(s).pdf
Scientific Editor Work List	6820-Scientific editor work list.doc